Desano Pharmaceuticals Co., Ltd. Held Company Annual Conference of 2018
Source：DESANO Date：2018-01-22 10:32:00Dr. Li Jinliang analyzed the situation of global market demand and domestic pharmaceuticals industry. Hepointed out that 2018 is the second year of the implementation of 5 years development strategy. Each department and company should integrate resources to improve market share and profitability of 7 first-line products - Lamivudine, Zidovudine, Nevirapine, Tenofovir, Efavirenz, Emtricitabine, Dolutegravir Sodium and to improve the cost competitiveness of second-line products and to promote the technical development of new products. We should promote the building of product line, initiate the construction of the second phase project of Jiangsu Puxin, initiate the construction of southern plant project of Yancheng Desano promote the approval and construction of the second phase project of Desano Chemical Pharmaceutical, implement in-depth investigation and analysis, promote the comprehensive treatment of three wastes to reach the compliance and standard emission. The conference also planned other priorities.
Mr. Li Jingpeng emphasized on that each department and company should refer to one-time quality compliance rate, realize the compliance and standard emission of three wastes, improve the stability of first-line staff by strengthening the skills and making up the deficiency to make efforts to fully realize the annual production and operation target of 2018.
